tiprankstipranks
Trending News
More News >

Cambium Bio Addresses Compliance Oversight

Story Highlights
  • Cambium Bio Limited addressed late lodgement of appendices due to an administrative oversight.
  • The company assured its compliance arrangements are adequate and the incident is unlikely to recur.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

The latest announcement is out from Regeneus Ltd. ( (AU:CMB) ).

Cambium Bio Limited, a company listed on the ASX under the ticker CMB, addressed queries regarding the late lodgement of certain appendices related to changes in directorship. The company attributed the delay to an administrative oversight and assured that its current compliance arrangements with the ASX Listing Rules are adequate and enforced. Cambium Bio emphasized that the late lodgement was an isolated incident and unlikely to recur.

More about Regeneus Ltd.

YTD Price Performance: -2.50%

Average Trading Volume: 22,662

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$5.52M

For detailed information about CMB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App